- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05784220
The Canadian Diabetes Prevention Program (CDPP)
Prevention of Type 2 Diabetes Using a Digital Wellness Coaching Intervention: The Canadian Diabetes Prevention Program
According to Diabetes Canada ("DC"), in 2015, the estimated prevalence of prediabetes in Canada (>20 years of age) is 5.7 million people (22.1%). This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently Type 2 Diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada .
There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage.
The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
INTRODUCTION:
LMC Healthcare, in collaboration with Diabetes Canada and INTERVENT International, is inviting participants to be part of a new program called the Canadian Diabetes Prevention Program ("CDPP") aimed at reducing the risk of developing Type 2 Diabetes. Participants can join the CDPP if participants have been diagnosed with prediabetes or participants score 33 or above on the CANRISK Questionnaire (a validated tool used to assess diabetes risk). Information collected from the CDPP will be used for research purposes.
BACKGROUND / RATIONALE:
According to Diabetes Canada ("DC"), in 2015, the estimated number of people with prediabetes in Canada (>20 years of age) was 5.7 million people (22.1%). Prediabetes can be defined as people with a blood sugar level that is higher than normal but not high enough to be diagnosed with diabetes; these people are at high risk for developing diabetes. This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently type 2 diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada.
There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.
The proposed intervention would target participants who are identified as "at risk" using the Canadian Diabetes Risk Assessment Questionnaire (CANRISK) or those participants who have been diagnosed with prediabetes based on blood work.
PURPOSE/OBJECTIVE:
To reduce the risk of developing Type 2 Diabetes Mellitus by taking part in a 12-month lifestyle intervention program. A select group of participants, 452 participants, will have a follow up at 18 months to assess a post-study progression.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4G 3E8
- LMC Diabetes Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Score of 33 or higher using the Canadian Diabetes Risk Assessment (CANRISK) Questionnaire (aged 18 to 74) or;
- Age ≥ 45 and BMI ≥ 30 or;
- Or diagnosed with prediabetes age 18 years or older with an A1c of 6.0-6.4% and/or fasting glucose 6.1-6.9 mmol/L and;
- Access to phone and internet (options include: home, work, friend's home, relative's home, public library, etc.);
Exclusion Criteria:
- Diagnosis of diabetes
- Any glucose lowering medication
- Any prescribed weight loss medication
- Receiving oral/systemic glucocorticoid (steroid) therapy (not including inhalers or nasal sprays) within the past 3 months, or planning to initiate oral/systemic glucocorticoid (steroid) in the next 3 months
- History of acute or chronic pancreatitis
- History of an active or untreated malignancy or in remission from a clinically significant malignancy for less than 5 years
- History of hemoglobinopathy, which may affect HbA1c measurement
- Currently enrolled in a clinical trial involving an investigational drug (need to be free of study medication for 30 days after final visit)
- Pregnancy or becoming pregnant during the study (the participant would be excluded due to weight gain and increased of waist circumference as they contradict the outcomes of the study)
- Dementia/severe cognitive impairment (the study does not have the proper support staff to support participants with specific needs)
- Inability to read English or French, or with personal or family support to interpret material
- Outside the catchment area for lab services (blood and anthropometric collection)
- Weight at baseline greater than upper limit of the scale used
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: DPP
The CDC Diabetes Prevention Program (DPP) curriculum for lifestyle intervention, including 21 education topics delivered via text-based education module, and follow-up telephone health coaching call for each topic.
|
See arms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in weight assessed by a scale
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
Change in weight assessed by a scale
Time Frame: 18 months from baseline
|
18 months from baseline
|
|
BMI < 25.0 and/or weight loss ≥ 5.0%
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
BMI < 25.0 and/or weight loss ≥ 5.0%
Time Frame: 18 months from baseline
|
18 months from baseline
|
|
Change in waist circumference assessed by measurement in waist circumference
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
> 3% and ≥ 5% reduction in waist circumference
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
> 3% and ≥ 5% reduction in waist circumference
Time Frame: 18 months from baseline
|
18 months from baseline
|
|
A1c at final visit <6.5% measured by lab test
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
A1c at final visit <6.5% measured by lab test
Time Frame: 18 months from baseline
|
18 months from baseline
|
|
Fasting blood glucose at final visit < 7 mmol/L measured by lab test
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
Fasting blood glucose at final visit < 7 mmol/L measured by lab test
Time Frame: 8 months from baseline
|
8 months from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants in each category and sub-category (of each question) of CANRISK Questionnaire
Time Frame: Baseline, 6 months and 12 months
|
Baseline, 6 months and 12 months
|
|
|
Number of participants that are diagnosed with prediabetes vs. at high risk
Time Frame: Baseline, 6 months and 12 months
|
Baseline, 6 months and 12 months
|
|
|
The number of people who develop diabetes during the program
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
Effectiveness of recruitment channels.
Time Frame: Baseline
|
The following choices will be given to participants to fill out and the participant will be able to choose all that apply: doctor or health care provider, social media (facebook, instagram, twitter) google/internet search, employer, recommendation from family/friend, and/or other.
|
Baseline
|
|
Intervention reach assessed by postal code
Time Frame: Baseline
|
Baseline
|
|
|
Participants knowledge about disease risk factors and lifestyle change assessed through the Knowledge Questionnaire
Time Frame: Baseline, 6 months and 12 months
|
Baseline, 6 months and 12 months
|
|
|
The proportion of individuals who lower their risk of diabetes (CANRISK score)
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
The proportion of participants who had an improvement in quality of life assessed by the SF-12 Questionnaire
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
The proportion of participants who had a change in diet, based on ASA-24 Questionnaire
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
The number of participants in each category of the stages of change assessed by the Stages of Change Questionnaire
Time Frame: Baseline, 6 months and 12 months
|
Baseline, 6 months and 12 months
|
|
|
Participants change in the stage of change assessed by Stages of Change Questionnaire
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
The number of participants who completed the program
Time Frame: 9 months
|
A completed participant is defined as someone who attended 56% of their sessions in the first 6 months of intervention, and at least 50% of their sessions in the last 6 months of their intervention, and has been in the program for a minimum of 9 months in total
|
9 months
|
|
Participant satisfaction by Participant Satisfaction Survey and Post Program Interview
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
The proportion of participants who had a change in physical activity
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
The proportion of participants who report a minimum of 150 minutes of moderate- to vigorous-intensity of physical activity spread across the week.
Time Frame: Baseline, 6 months and 12 months
|
The INTERVENT platform has the ability to measure participants' steps if they have a step-counter; therefore, the amount of time will be identified as self-reported or through a step counter.
|
Baseline, 6 months and 12 months
|
|
Change in LDL-c and non-HDL (subgroup analyses for people on cholesterol lowering medications vs. no cholesterol lowering medications during the project)
Time Frame: 12 months
|
12 months
|
|
|
Change in HDL
Time Frame: 12 months
|
12 months
|
|
|
Change in triglycerides
Time Frame: 12 months
|
12 months
|
|
|
Proportion of subjects with improvement of triglyceride levels within normal limit for the lab
Time Frame: 12 months
|
12 months
|
|
|
Change in blood pressure
Time Frame: 12 months
|
Both systolic and diastolic blood pressure will be measured.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of reported technical issues related to software
Time Frame: 12 months
|
12 months
|
|
|
Level of participant engagement
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
|
Issues with delivery by service providers
Time Frame: 12 months from baseline
|
12 months from baseline
|
|
|
Subjective scoring of program coach audits
Time Frame: 12 months from baseline
|
0-10, A higher number is a better result
|
12 months from baseline
|
|
Objective scoring of program coach audits
Time Frame: 12 months from baseline
|
0-5.
A higher number is a better result
|
12 months from baseline
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDPP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes type2
-
Bangladesh Medical UniversityEnrolling by invitationType2 Diabetes MellitusBangladesh
-
Chonticha KaewjohoUniversity of PhayaoCompletedType2 Diabetes Mellitus | Autonomic Nervous System ImbalanceThailand
-
Mathias Ried-LarsenCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Mariam Emeel Haleem NaseemNot yet recruitingType2 Diabetes Mellitus | CKD Stage 1-4 | Diet Pattern Analysis
-
Johns Hopkins UniversityUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedHypertension | Diabetes Mellitus, Type 2 | Diabetes | Diabetes type2 | Type 2 Diabetes | Type2 Diabetes | Type II Diabetes | High Blood PressureUnited States
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
NYU Langone HealthNot yet recruitingType2 Diabetes MellitusUnited States
-
Region SkaneActive, not recruiting
-
Michigan State UniversityUniversity of Michigan; Claremont Graduate UniversityCompleted
-
University of ChicagoCompleted
Clinical Trials on DPP Curriculum for Lifestyle Intervention
-
Albert Einstein College of MedicineNew York Presbyterian Hospital; Chinese American Independent Practice Association... and other collaboratorsCompleted
-
University of ArkansasNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPreDiabetes | Type 2 Diabetes | Obesity, Childhood | Overweight and Obesity | Lifestyle, Healthy | Overweight, ChildhoodUnited States
-
University of California, Los AngelesPatient-Centered Outcomes Research InstituteCompletedObesityUnited States
-
University of ArkansasCompletedOverweight | Memory Disorder
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | Cardiovascular Risk Factor | Diabetes Mellitus Risk
-
University of Alabama at BirminghamCompletedObesityUnited States
-
The University of Tennessee, KnoxvilleTerminatedBreast Cancer | Sedentary LifestyleUnited States
-
Université de SherbrookeCanadian Institutes of Health Research (CIHR); Ministere de la Sante et des...CompletedObesity | Polycystic Ovary Syndrome | Female InfertilityCanada
-
University of California, Los AngelesRecruiting